Given the association linking critical and fatal COVID-19 with increased pro-inflammatory cytokines, including IL-6, tocilizumab has been approved by some regulatory agencies to treat COVID-19 in adults receiving systemic corticosteroids, supplemental oxygen, or who are under mechanical ventilation (Actemra/RoActemra, 2022). The gene discussed is IL6; the disease is COVID-19.